Table 1

Serology, HLA-DQ status, and inferred prevalence of CD
Total HLA-DQ 2.5/8/2.2-positive, observed,(expected) n HLA-DQ 2.5/8/2.2-positive, RR (95% CI) Excess HLA-DQ 2.5/8/2.2-positive, n Prevalence per 1.000 (95% CI)
Biopsy-confirmed CD
 F + M 356 351 1.78 (1.71 to 1.84)a NA
Biopsy-confirmed CD; four of five HLA-DQ2.5-DQ8-DQ2.2- re-investigated
 F + M 352 351 1.80 (1.73 to 1.89)a NA
Community random sample of age-stratified cohorts of adults
 F 1,065 596 1 0
 M 921 513 1 0
Community sample: initially positive for TG2 IgA
 F 48 34 (27) 1.28 (1.06 to 1.55)b 14 13.4 (2.4 to 26.8)
 M 68 44 (38) 1.18 (0.98 to 1.42)NS 12 13.2 (−2.9 to 32.8)
Community sample: initially positive for TG2 IgA, and confirmed positive for EMA
 F 13 13 (7) 1.80 (1.71 to 1.90)c 11 10.8 (9.5 to 12.1)
 M 13 13 (7) 1.82 (1.71 to 1.93)c 12 12.5 (10.9 to 14.2)
Community sample: initially positive for composite TG2/DGP IgA/IgG
 F 55 41 (31) 1.36 (1.15 to 1.60)d 20 19.2 (7.5 to 32.9)
 M 73 46 (41) 1.14 (0.95 to 1.38) NS 11 11.6 (−5.4 to 32.0)
Community sample: initially positive for composite TG2/DGP IgA/IgG, and confirmed positive for TG2 IgA, DGP-G-+, or DGP-A
 F 37 30 (21) 1.47 (1.23 to 1.74)e 19 17.5 (8.9 to 27.6)
 M 44 29 (25) 1.19 (0.96 to 1.49) NS 9 9.8 (−2.7 to 25.3)
Community sample: – initially positive for TG2/DGP IgA/IgG, and confirmed positive for TG2 IgA, DGP-G, and DGP-A
 F 10 10 (6) 1.80 (1.71 to 1.90)d 9 8.3 (7.3 to 9.3)
 M 11 11 (6) 1.82 (1.72 to 1.93)e 10 10.6 (9.3 to 12.1)

Abbreviations: CD, celiac disease; DGP, Deamidated gliadin-derived peptide; EMA, endomysial immunofluorescence IgA; F, female; HLA, human leukocyte antigen; Ig, immunoglobulin; M, male; NA, not applicable; NS, not significant; RR, relative risk; TG2, transglutaminase-2.

Compared with community M + F: aP<0.0001 (χ2 two-tailed); bP<0.04, cP<0.001, dP<0.005, eP<0.002, (Fisher’s exact test, two-tailed).

Anderson et al.

Anderson et al. BMC Medicine 2013 11:188   doi:10.1186/1741-7015-11-188

Open Data